Published in Mol Immunol on February 01, 2005
The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J Exp Med (2005) 6.86
HMGB1: endogenous danger signaling. Mol Med (2008) 4.02
RAGE (Receptor for Advanced Glycation Endproducts), RAGE ligands, and their role in cancer and inflammation. J Transl Med (2009) 2.56
HMGB1 in health and disease. Mol Aspects Med (2014) 1.67
Activated protein C inhibits high mobility group box 1 signaling in endothelial cells. Blood (2011) 1.22
Damage associated molecular pattern molecules. Clin Immunol (2007) 1.19
HMGB1: The Central Cytokine for All Lymphoid Cells. Front Immunol (2013) 1.18
Complete regression and systemic protective immune responses obtained in B16 melanomas after treatment with LTX-315. Cancer Immunol Immunother (2014) 1.08
Toll-like receptors and innate immune responses in systemic lupus erythematosus. Arthritis Res Ther (2007) 1.07
Pathogenic anti-DNA antibodies modulate gene expression in mesangial cells: involvement of HMGB1 in anti-DNA antibody-induced renal injury. Immunol Lett (2008) 1.04
Prevalence and clinical significance of sterile intra-amniotic inflammation in patients with preterm labor and intact membranes. Am J Reprod Immunol (2014) 1.04
Pattern recognition receptors and central nervous system repair. Exp Neurol (2014) 1.02
Toll-like receptors expression and interferon-γ production by NK cells in human sepsis. Crit Care (2012) 0.98
Caspase-1 is hepatoprotective during trauma and hemorrhagic shock by reducing liver injury and inflammation. Mol Med (2011) 0.95
LNFPIII/LeX-stimulated macrophages activate natural killer cells via CD40-CD40L interaction. Clin Diagn Lab Immunol (2005) 0.94
Ménage à Trois in stress: DAMPs, redox and autophagy. Semin Cancer Biol (2013) 0.89
Immunological aspects and therapeutic significance of an autoantibody against histone H1 in a rat model of concanavalin A-induced hepatitis. Immunology (2009) 0.85
HMGB1 enhances smooth muscle cell proliferation and migration in pulmonary artery remodeling. Int J Clin Exp Pathol (2014) 0.85
The protective effect of lidocaine on septic rats via the inhibition of high mobility group box 1 expression and NF-κB activation. Mediators Inflamm (2013) 0.85
Potential functional role of plasmacytoid dendritic cells in cancer immunity. Immunology (2007) 0.84
Expression and effects of high-mobility group box 1 in cervical cancer. Int J Mol Sci (2014) 0.82
HMGB1 gene polymorphisms in patients with chronic hepatitis B virus infection. World J Gastroenterol (2013) 0.81
Temporal and spatial expression of high-mobility group box 1 in surgically injured rat vocal folds. Laryngoscope (2012) 0.81
Exercise training and immune crosstalk in breast cancer microenvironment: exploring the paradigms of exercise-induced immune modulation and exercise-induced myokines. Am J Transl Res (2014) 0.81
Effects of lower concentration thrombin on high-mobility group box 1 protein-mediated inflammatory responses. Inflammation (2012) 0.81
High mobility group box 1 and adenosine are both released by endothelial cells during hypothermic preservation. Clin Exp Immunol (2008) 0.80
Amino acid residues 201-205 in C-terminal acidic tail region plays a crucial role in antibacterial activity of HMGB1. J Biomed Sci (2009) 0.78
The dual role of NK cells in antitumor reactions triggered by ionizing radiation in combination with hyperthermia. Oncoimmunology (2016) 0.76
Intercellular Communication of Tumor Cells and Immune Cells after Exposure to Different Ionizing Radiation Qualities. Front Immunol (2017) 0.75
MICA-expressing monocytes enhance natural killer cell Fc receptor-mediated antitumor functions. Cancer Immunol Res (2017) 0.75
2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med (2003) 28.68
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med (2003) 10.39
Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci U S A (2003) 7.14
The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J Exp Med (2005) 6.86
Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study. Arch Intern Med (2007) 5.65
Principles and current strategies for targeting autophagy for cancer treatment. Clin Cancer Res (2011) 5.40
The CRIT Study: Anemia and blood transfusion in the critically ill--current clinical practice in the United States. Crit Care Med (2004) 5.23
Interleukin-17 promotes angiogenesis and tumor growth. Blood (2002) 4.90
Endogenous HMGB1 regulates autophagy. J Cell Biol (2010) 4.71
Efficacy of recombinant human erythropoietin in critically ill patients: a randomized controlled trial. JAMA (2002) 4.09
Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation. Proc Natl Acad Sci U S A (2002) 3.68
Inflammation and necrosis promote tumour growth. Nat Rev Immunol (2004) 3.68
High-mobility group box 1 and cancer. Biochim Biophys Acta (2010) 3.11
IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis. J Immunol (2005) 3.02
Interleukin-12: biological properties and clinical application. Clin Cancer Res (2007) 3.00
HMGB1 B box increases the permeability of Caco-2 enterocytic monolayers and impairs intestinal barrier function in mice. Gastroenterology (2002) 2.95
Inside, outside, upside down: damage-associated molecular-pattern molecules (DAMPs) and redox. Trends Immunol (2007) 2.81
Hepatic ischemia/reperfusion injury involves functional TLR4 signaling in nonparenchymal cells. J Immunol (2005) 2.78
Critical care medicine training and certification for emergency physicians. Ann Emerg Med (2005) 2.67
RAGE (Receptor for Advanced Glycation Endproducts), RAGE ligands, and their role in cancer and inflammation. J Transl Med (2009) 2.56
Masquerader: high mobility group box-1 and cancer. Clin Cancer Res (2007) 2.40
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Structural basis for the proinflammatory cytokine activity of high mobility group box 1. Mol Med (2003) 2.30
Anti-HMGB1 neutralizing antibody ameliorates gut barrier dysfunction and improves survival after hemorrhagic shock. Mol Med (2006) 2.27
PAMPs and DAMPs: signal 0s that spur autophagy and immunity. Immunol Rev (2012) 2.24
High-mobility group box 1, oxidative stress, and disease. Antioxid Redox Signal (2011) 2.19
Systemic inflammation and remote organ injury following trauma require HMGB1. Am J Physiol Regul Integr Comp Physiol (2007) 2.12
Critical care medicine training and certification for emergency physicians. Crit Care Med (2005) 2.12
Haloperidol use is associated with lower hospital mortality in mechanically ventilated patients. Crit Care Med (2005) 2.11
A comparison of critical care research funding and the financial burden of critical illness in the United States. Crit Care Med (2012) 2.07
Targeting mitochondria. Acc Chem Res (2008) 2.03
Measures, markers, and mediators: toward a staging system for clinical sepsis. A report of the Fifth Toronto Sepsis Roundtable, Toronto, Ontario, Canada, October 25-26, 2000. Crit Care Med (2003) 2.01
Dicer-regulated microRNAs 222 and 339 promote resistance of cancer cells to cytotoxic T-lymphocytes by down-regulation of ICAM-1. Proc Natl Acad Sci U S A (2009) 1.94
Interleukin-1F7B (IL-1H4/IL-1F7) is processed by caspase-1 and mature IL-1F7B binds to the IL-18 receptor but does not induce IFN-gamma production. Cytokine (2002) 1.92
High-mobility group box 1 is essential for mitochondrial quality control. Cell Metab (2011) 1.89
Addicted to death: invasive cancer and the immune response to unscheduled cell death. J Immunother (2004) 1.88
Ethyl pyruvate ameliorates distant organ injury in a murine model of acute necrotizing pancreatitis. Crit Care Med (2004) 1.88
The acute inflammatory response in diverse shock states. Shock (2005) 1.83
Second-generation tetracycline-regulatable promoter: repositioned tet operator elements optimize transactivator synergy while shorter minimal promoter offers tight basal leakiness. J Gene Med (2004) 1.80
Autophagy inhibition in combination cancer treatment. Curr Opin Investig Drugs (2009) 1.79
HMGB1 in cancer: good, bad, or both? Clin Cancer Res (2013) 1.79
Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation. Proc Natl Acad Sci U S A (2010) 1.72
Cancer and inflammation: promise for biologic therapy. J Immunother (2010) 1.72
Ethyl pyruvate ameliorates acute alcohol-induced liver injury and inflammation in mice. J Lab Clin Med (2003) 1.71
Ethyl pyruvate modulates inflammatory gene expression in mice subjected to hemorrhagic shock. Am J Physiol Gastrointest Liver Physiol (2002) 1.70
IL-6 is essential for development of gut barrier dysfunction after hemorrhagic shock and resuscitation in mice. Am J Physiol Gastrointest Liver Physiol (2003) 1.70
Toll-like receptor-4 signaling mediates hepatic injury and systemic inflammation in hemorrhagic shock. J Am Coll Surg (2006) 1.57
Feature Selection for Classification of SELDI-TOF-MS Proteomic Profiles. Appl Bioinformatics (2005) 1.56
HMGB1 is secreted by immunostimulated enterocytes and contributes to cytomix-induced hyperpermeability of Caco-2 monolayers. Am J Physiol Cell Physiol (2005) 1.51
Ethyl pyruvate inhibits nuclear factor-kappaB-dependent signaling by directly targeting p65. J Pharmacol Exp Ther (2004) 1.51
Mitochondrial targeting of selective electron scavengers: synthesis and biological analysis of hemigramicidin-TEMPO conjugates. J Am Chem Soc (2005) 1.50
Ethyl pyruvate improves systemic and hepatosplanchnic hemodynamics and prevents lipid peroxidation in a porcine model of resuscitated hyperdynamic endotoxemia. Crit Care Med (2005) 1.49
Interleukin-17 enhances bFGF-, HGF- and VEGF-induced growth of vascular endothelial cells. Immunol Lett (2004) 1.46
Increased iNOS activity is essential for intestinal epithelial tight junction dysfunction in endotoxemic mice. Shock (2004) 1.46
High mobility group box I (HMGB1) release from tumor cells after treatment: implications for development of targeted chemoimmunotherapy. J Immunother (2007) 1.45
Ethyl pyruvate decreases HMGB1 release and ameliorates murine colitis. J Leukoc Biol (2009) 1.45
The biochemical basis for the anti-inflammatory and cytoprotective actions of ethyl pyruvate and related compounds. Biochem Pharmacol (2010) 1.43
Intensive care and emergency medicine: progress over the past 25 years. Chest (2006) 1.43
High-mobility group box 1 activates caspase-1 and promotes hepatocellular carcinoma invasiveness and metastases. Hepatology (2012) 1.42
Cutting edge: high-mobility group box 1 preconditioning protects against liver ischemia-reperfusion injury. J Immunol (2006) 1.42
Complementary dendritic cell-activating function of CD8+ and CD4+ T cells: helper role of CD8+ T cells in the development of T helper type 1 responses. J Exp Med (2002) 1.41
p53/HMGB1 complexes regulate autophagy and apoptosis. Cancer Res (2012) 1.41
Systemic inflammation and remote organ damage following bilateral femur fracture requires Toll-like receptor 4. Am J Physiol Regul Integr Comp Physiol (2006) 1.40
Eosinophilic granulocytes and damage-associated molecular pattern molecules (DAMPs): role in the inflammatory response within tumors. J Immunother (2007) 1.39
Structural requirements for optimized delivery, inhibition of oxidative stress, and antiapoptotic activity of targeted nitroxides. J Pharmacol Exp Ther (2006) 1.36
Resuscitation from hemorrhagic shock with Ringer's ethyl pyruvate solution improves survival and ameliorates intestinal mucosal hyperpermeability in rats. Shock (2002) 1.35
The enhanced tumor selectivity of an oncolytic vaccinia lacking the host range and antiapoptosis genes SPI-1 and SPI-2. Cancer Res (2005) 1.34
Prolonged treatment with N-acetylcystine delays liver recovery from acetaminophen hepatotoxicity. Crit Care (2009) 1.32
Quercetin prevents LPS-induced high-mobility group box 1 release and proinflammatory function. Am J Respir Cell Mol Biol (2009) 1.32
Receptor-mediated signalling in plants: molecular patterns and programmes. J Exp Bot (2009) 1.31
Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology. J Transl Med (2009) 1.31
Interleukin-17 augments tumor necrosis factor-alpha-induced elaboration of proangiogenic factors from fibroblasts. Immunol Lett (2004) 1.30
The expression of the receptor for advanced glycation endproducts (RAGE) is permissive for early pancreatic neoplasia. Proc Natl Acad Sci U S A (2012) 1.30
Blood soluble drag-reducing polymers prevent lethality from hemorrhagic shock in acute animal experiments. Biorheology (2004) 1.29
Proinflammatory cytokines cause NO*-dependent and -independent changes in expression and localization of tight junction proteins in intestinal epithelial cells. Shock (2003) 1.28
Increasing numbers of hepatic dendritic cells promote HMGB1-mediated ischemia-reperfusion injury. J Leukoc Biol (2006) 1.27
High mobility group box 1 (HMGB1) activates an autophagic response to oxidative stress. Antioxid Redox Signal (2011) 1.27
In silico and in vivo approach to elucidate the inflammatory complexity of CD14-deficient mice. Mol Med (2006) 1.25
Dealing with death: HMGB1 as a novel target for cancer therapy. Curr Opin Investig Drugs (2003) 1.24
A Janus tale of two active high mobility group box 1 (HMGB1) redox states. Mol Med (2012) 1.21
Cell-mediated autophagy promotes cancer cell survival. Cancer Res (2012) 1.21
Damage associated molecular pattern molecules. Clin Immunol (2007) 1.19
Ethyl pyruvate ameliorates liver ischemia-reperfusion injury by decreasing hepatic necrosis and apoptosis. Transplantation (2005) 1.19
HMGB1: The Central Cytokine for All Lymphoid Cells. Front Immunol (2013) 1.18
Editorial: Hemopexin: newest member of the anti-inflammatory mediator club. J Leukoc Biol (2009) 1.17
Inhibiting systemic autophagy during interleukin 2 immunotherapy promotes long-term tumor regression. Cancer Res (2012) 1.17
Cytolytic cells induce HMGB1 release from melanoma cell lines. J Leukoc Biol (2006) 1.14
In silico models of acute inflammation in animals. Shock (2006) 1.14
Clinical tests of gastrointestinal permeability that rely on the urinary recovery of enterally administered probes can yield invalid results in critically ill patients. Intensive Care Med (2002) 1.12
Natural killer-dendritic cell cross-talk in cancer immunotherapy. Expert Opin Biol Ther (2005) 1.11
Evidence that glutathione depletion is a mechanism responsible for the anti-inflammatory effects of ethyl pyruvate in cultured lipopolysaccharide-stimulated RAW 264.7 cells. J Pharmacol Exp Ther (2003) 1.10
Increased iNOS activity is essential for pulmonary epithelial tight junction dysfunction in endotoxemic mice. Am J Physiol Lung Cell Mol Physiol (2003) 1.10
Tumor-cell death, autophagy, and immunity. N Engl J Med (2012) 1.10